Asp3082: Clinical Trials

2 trials of Asp3082, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Recruiting 2

Follow Asp3082: new trials by email Literature Review of Asp3082 trials Research Report on Asp3082

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Setidegrasib, Docetaxel - Non-small Cell Lung Cancer (NSCLC)
Phase 3RecruitingAstellas Pharma Global Development, Inc.3562026-08-192026-11-09
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer
Phase 3RecruitingAstellas Pharma Global Development, Inc.6142026-02-172026-11-03

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Pancreatic Neoplasms (1)

Sponsors

Astellas Pharma Global Development, Inc. (2)

Countries

China (2)  ·  Japan (2)  ·  United States (2)  ·  Brazil (1)  ·  France (1)  ·  Germany (1)  ·  Poland (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)